Detalhe da pesquisa
1.
Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.
J Infect Chemother
; 30(3): 271-275, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944697